Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $3.1 million.

  • Arcadia Biosciences' Total Liabilities fell 3831.5% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 3831.5%. This contributed to the annual value of $7.3 million for FY2024, which is 417.02% up from last year.
  • As of Q3 2025, Arcadia Biosciences' Total Liabilities stood at $3.1 million, which was down 3831.5% from $3.3 million recorded in Q2 2025.
  • Arcadia Biosciences' 5-year Total Liabilities high stood at $28.1 million for Q2 2021, and its period low was $3.1 million during Q3 2025.
  • For the 5-year period, Arcadia Biosciences' Total Liabilities averaged around $10.1 million, with its median value being $8.1 million (2023).
  • As far as peak fluctuations go, Arcadia Biosciences' Total Liabilities tumbled by 7069.6% in 2022, and later surged by 6031.32% in 2023.
  • Arcadia Biosciences' Total Liabilities (Quarter) stood at $12.7 million in 2021, then tumbled by 36.94% to $8.0 million in 2022, then dropped by 12.72% to $7.0 million in 2023, then increased by 4.17% to $7.3 million in 2024, then plummeted by 56.94% to $3.1 million in 2025.
  • Its Total Liabilities stands at $3.1 million for Q3 2025, versus $3.3 million for Q2 2025 and $4.1 million for Q1 2025.